Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27593132 | 0.87 | MTNR1A (0.63) | HPGDTAAR1MTNR1AMTNR1B | |
| SCHEMBL2151096 | 0.85 | HPGD (0.55) | HPGDTAAR1MEN1KMT2AMTNR1A | |
| SCHEMBL613087 | 0.85 | DRD2 (0.50) | HPGDMEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL11896371 | 0.81 | MTNR1A (0.77) | HPGDTAAR1MEN1KMT2AMTNR1A | |
| SCHEMBL613638 | 0.80 | PTGES (0.60) | TAAR1MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL13725463 | 0.79 | MTNR1A (0.79) | MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL10235798 | 0.78 | ABCB1 (0.58) | TAAR1 | |
| SCHEMBL612714 | 0.77 | TAAR1 (0.60) | TAAR1 | |
| SCHEMBL378759 | 0.75 | NPC1 (0.62) | MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL3843280 | 0.75 | ABCB1 (0.61) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450527-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2111223-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009058216-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | HPGD 312/4885TAAR1 120/4885MEN1 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.